Vinay Mehta1,2, Alexander Albers3,4, Maharaj Singh4,5, Ana Cristina Perez Moreno4, Timothy E Paterick6. 1. Department of Electrophysiology, Aurora BayCare Medical Center, 2845 Greenbrier Road, Ste. 330, Green Bay, WI 54311 USA. 2. Dr. Mehta's current affiliation is Nuvance Health, Danbury, Connecticut. 3. Department of Clinical Research, Aurora BayCare Medical Center, 2845 Greenbrier Road, Room 519, Green Bay, WI 54311 USA. 4. Aurora Research Institute, Aurora Health Care, 945 N. 12th St., Milwaukee, WI 53233 USA. 5. Dr. Singh's current affiliation is School of Dentistry, Marquette University, Milwaukee, Wisconsin. 6. Department of Cardiovascular Disease, Aurora BayCare Medical Center, 2845 Greenbrier Road, Ste. 330, Green Bay, WI 54311 USA.
Abstract
OBJECTIVE: There is limited research comparing demographic and clinical characteristics between patients who present with atrial fibrillation (AF) and new-onset cardiomyopathy (CM) to patients with new-onset CM without dysrhythmia. We aimed to evaluate clinical characteristics and outcomes in patients with new-onset CM with and without AF and to report their real-world treatment. METHODS AND RESULTS: The study population was identified using patient records from our healthcare system from January 1, 2012 to September 30, 2016. Patients with a left ventricular ejection fraction ≤40% without a prior history of CM were divided into two groups; those with an antecedent or concomitant diagnosis of AF (AF-CM group) and those with no history of dysrhythmia (CM group). Patients in the AF-CM group (n=196) were older, more likely to be male, had a higher burden of comorbidities but lower levels of cardiac biomarkers, and had lower voltage on surface electrocardiogram than the CM group (n=197). In AF-CM, symptom onset was insidious, leading to a higher likelihood of outpatient diagnosis; 88.3% of AF-CM patients presented with atypical symptoms of AF. The AF-CM group had higher mortality on follow-up. Only 8.7% of patients in this group underwent an ablation procedure. Women, those with a history of coronary artery disease, and older patients were less likely to receive a cardioversion or ablation procedure. CONCLUSIONS: Patients presenting with new-onset CM associated with AF have a markedly different risk factor and demographic profile, clinical presentation, and outcomes. In real-world practice, a minority of patients undergo a rhythm control strategy.
OBJECTIVE: There is limited research comparing demographic and clinical characteristics between patients who present with atrial fibrillation (AF) and new-onset cardiomyopathy (CM) to patients with new-onset CM without dysrhythmia. We aimed to evaluate clinical characteristics and outcomes in patients with new-onset CM with and without AF and to report their real-world treatment. METHODS AND RESULTS: The study population was identified using patient records from our healthcare system from January 1, 2012 to September 30, 2016. Patients with a left ventricular ejection fraction ≤40% without a prior history of CM were divided into two groups; those with an antecedent or concomitant diagnosis of AF (AF-CM group) and those with no history of dysrhythmia (CM group). Patients in the AF-CM group (n=196) were older, more likely to be male, had a higher burden of comorbidities but lower levels of cardiac biomarkers, and had lower voltage on surface electrocardiogram than the CM group (n=197). In AF-CM, symptom onset was insidious, leading to a higher likelihood of outpatient diagnosis; 88.3% of AF-CM patients presented with atypical symptoms of AF. The AF-CM group had higher mortality on follow-up. Only 8.7% of patients in this group underwent an ablation procedure. Women, those with a history of coronary artery disease, and older patients were less likely to receive a cardioversion or ablation procedure. CONCLUSIONS: Patients presenting with new-onset CM associated with AF have a markedly different risk factor and demographic profile, clinical presentation, and outcomes. In real-world practice, a minority of patients undergo a rhythm control strategy.
Authors: Sandeep A Kamath; Januario de P Meo Neto; Russell M Canham; Fatema Uddin; Kathleen H Toto; Lauren L Nelson; Patricia A Kaiser; James A de Lemos; Mark H Drazner Journal: Am Heart J Date: 2006-08 Impact factor: 4.749
Authors: Michiel Rienstra; Rob A Vermond; Harry J G M Crijns; Jan G P Tijssen; Isabelle C Van Gelder Journal: Heart Rhythm Date: 2014-03-13 Impact factor: 6.343
Authors: Arnold F Jacobson; Roxy Senior; Manuel D Cerqueira; Nathan D Wong; Gregory S Thomas; Victor A Lopez; Denis Agostini; Fred Weiland; Harish Chandna; Jagat Narula Journal: J Am Coll Cardiol Date: 2010-02-25 Impact factor: 24.094
Authors: Julie L Hejl; Mia K Grand; Volkert Siersma; Jens P Goetze; Niels de Fine Olivarius; Christen L Andersen; Bent Lind Journal: Clin Chem Date: 2018-10-15 Impact factor: 8.327
Authors: Jonathan P Piccini; Bradley G Hammill; Moritz F Sinner; Adrian F Hernandez; Allan J Walkey; Emelia J Benjamin; Lesley H Curtis; Susan R Heckbert Journal: Eur Heart J Date: 2013-11-25 Impact factor: 29.983
Authors: W H Wilson Tang; John P Girod; Michael J Lee; Randall C Starling; James B Young; Frederick Van Lente; Gary S Francis Journal: Circulation Date: 2003-12-08 Impact factor: 29.690
Authors: Sandeep Prabhu; Andrew J Taylor; Ben T Costello; David M Kaye; Alex J A McLellan; Aleksandr Voskoboinik; Hariharan Sugumar; Siobhan M Lockwood; Michael B Stokes; Bhupesh Pathik; Chrishan J Nalliah; Geoff R Wong; Sonia M Azzopardi; Sarah J Gutman; Geoffrey Lee; Jamie Layland; Justin A Mariani; Liang-Han Ling; Jonathan M Kalman; Peter M Kistler Journal: J Am Coll Cardiol Date: 2017-08-27 Impact factor: 24.094